Novel advances in pancreatic cancer treatment

Michel Vulfovich, Caio Rocha-Lima

Research output: Contribution to journalArticle

43 Citations (Scopus)

Abstract

Little progress has been made on the treatment of advanced pancreatic cancer. Gemcitabine has been an acceptable standard for more than a decade. The benefit of single-agent gemcitabine in advanced and metastatic pancreatic cancer is small. Adding other chemotherapy agents to gemcitabine has not resulted in meaningful improvement In survival. The randomized trials studying the addition of molecular targeting agents (cetuximab, bevacizumab, farnesyl transferase inhibitors and metalloproteinase inhibitors) to gemcitabine compared with gemcitabine alone have been disappointing. A small gain in median survival by adding erlotinib to gemcitabine has recently been reported. We herein review novel agents in pancreatic cancer that may change the current nihilistic approach in the management of this challenging disease.

Original languageEnglish
Pages (from-to)993-1002
Number of pages10
JournalExpert Review of Anticancer Therapy
Volume8
Issue number6
DOIs
StatePublished - Sep 2 2008

Fingerprint

gemcitabine
Pancreatic Neoplasms
Therapeutics
Metalloproteases
Disease Management
Transferases
Drug Therapy

Keywords

  • Epithelial growth factor
  • Monoclonal antibodies
  • Pancreatic cancer
  • Targeted therapies
  • Vascular endothelial growth factor
  • VEGF

ASJC Scopus subject areas

  • Pharmacology
  • Cancer Research

Cite this

Novel advances in pancreatic cancer treatment. / Vulfovich, Michel; Rocha-Lima, Caio.

In: Expert Review of Anticancer Therapy, Vol. 8, No. 6, 02.09.2008, p. 993-1002.

Research output: Contribution to journalArticle

Vulfovich, Michel ; Rocha-Lima, Caio. / Novel advances in pancreatic cancer treatment. In: Expert Review of Anticancer Therapy. 2008 ; Vol. 8, No. 6. pp. 993-1002.
@article{0e8dfb270859438393c12b598fdc5805,
title = "Novel advances in pancreatic cancer treatment",
abstract = "Little progress has been made on the treatment of advanced pancreatic cancer. Gemcitabine has been an acceptable standard for more than a decade. The benefit of single-agent gemcitabine in advanced and metastatic pancreatic cancer is small. Adding other chemotherapy agents to gemcitabine has not resulted in meaningful improvement In survival. The randomized trials studying the addition of molecular targeting agents (cetuximab, bevacizumab, farnesyl transferase inhibitors and metalloproteinase inhibitors) to gemcitabine compared with gemcitabine alone have been disappointing. A small gain in median survival by adding erlotinib to gemcitabine has recently been reported. We herein review novel agents in pancreatic cancer that may change the current nihilistic approach in the management of this challenging disease.",
keywords = "Epithelial growth factor, Monoclonal antibodies, Pancreatic cancer, Targeted therapies, Vascular endothelial growth factor, VEGF",
author = "Michel Vulfovich and Caio Rocha-Lima",
year = "2008",
month = "9",
day = "2",
doi = "10.1586/14737140.8.6.993",
language = "English",
volume = "8",
pages = "993--1002",
journal = "Expert Review of Anticancer Therapy",
issn = "1473-7140",
publisher = "Expert Reviews Ltd.",
number = "6",

}

TY - JOUR

T1 - Novel advances in pancreatic cancer treatment

AU - Vulfovich, Michel

AU - Rocha-Lima, Caio

PY - 2008/9/2

Y1 - 2008/9/2

N2 - Little progress has been made on the treatment of advanced pancreatic cancer. Gemcitabine has been an acceptable standard for more than a decade. The benefit of single-agent gemcitabine in advanced and metastatic pancreatic cancer is small. Adding other chemotherapy agents to gemcitabine has not resulted in meaningful improvement In survival. The randomized trials studying the addition of molecular targeting agents (cetuximab, bevacizumab, farnesyl transferase inhibitors and metalloproteinase inhibitors) to gemcitabine compared with gemcitabine alone have been disappointing. A small gain in median survival by adding erlotinib to gemcitabine has recently been reported. We herein review novel agents in pancreatic cancer that may change the current nihilistic approach in the management of this challenging disease.

AB - Little progress has been made on the treatment of advanced pancreatic cancer. Gemcitabine has been an acceptable standard for more than a decade. The benefit of single-agent gemcitabine in advanced and metastatic pancreatic cancer is small. Adding other chemotherapy agents to gemcitabine has not resulted in meaningful improvement In survival. The randomized trials studying the addition of molecular targeting agents (cetuximab, bevacizumab, farnesyl transferase inhibitors and metalloproteinase inhibitors) to gemcitabine compared with gemcitabine alone have been disappointing. A small gain in median survival by adding erlotinib to gemcitabine has recently been reported. We herein review novel agents in pancreatic cancer that may change the current nihilistic approach in the management of this challenging disease.

KW - Epithelial growth factor

KW - Monoclonal antibodies

KW - Pancreatic cancer

KW - Targeted therapies

KW - Vascular endothelial growth factor

KW - VEGF

UR - http://www.scopus.com/inward/record.url?scp=47249118032&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=47249118032&partnerID=8YFLogxK

U2 - 10.1586/14737140.8.6.993

DO - 10.1586/14737140.8.6.993

M3 - Article

C2 - 18533808

AN - SCOPUS:47249118032

VL - 8

SP - 993

EP - 1002

JO - Expert Review of Anticancer Therapy

JF - Expert Review of Anticancer Therapy

SN - 1473-7140

IS - 6

ER -